Kasim Kutay, CEO of Novo Holdings, said: “With her extensive market knowledge and executive experience in the pharmaceutical and life science industries, Meeta brings valuable insights to our Advisory Group’s work. I am delighted to welcome Meeta on board and very much look forward to her contributions.”

Meeta Gulyani has over two and half decades of international experience working with business-wide strategic development and implementation, driving large-scale transformation and delivering strong operating performance. In her most recent position for Millipore Sigma, the Life Science Division of Merck KGaA, Darmstadt, Germany, she was responsible for the organisation’s long-term strategy, business development and sustainability agenda. In addition, following the USD 17 Billion acquisition of the chemical giant Sigma-Aldrich, she led its successful integration. Meeta was previously the Head of Strategy and Global Franchises for the Biopharma business of Merck KGaA, Darmstadt, Germany.

Before joining Merck KGaA, Darmstadt Germany in 2014, Meeta served as General Manager for Roche South Asia, and Vice President, Head of Global Portfolio Management at Roche. In addition, she has held several marketing and sales leadership positions within Sanofi and served as a strategy consultant with the Monitor Consulting Group based in Hong Kong and the United States.

Meeta Gulyani said: “It’s an honour for me to join the Novo Advisory Group. I look forward to being able to draw on my industry experience and contribute to Novo Holdings’ important mission of generating attractive financial returns to improve people’s health and the sustainability of society and the planet.”